Crinetics' Acromegaly Drug Shows Promise in Phase 3 Trial, Faces Tough Competition

Crinetics Pharmaceuticals' experimental drug for acromegaly, a rare hormonal disorder, has shown success in a late-stage trial, with 25 out of 30 patients given the drug achieving normal growth-factor levels compared to just 1 out of 28 participants who took the placebo. The company plans to file for FDA approval pending positive results from a second Phase 3 trial. However, if approved, Crinetics would face tough competition from existing blockbuster therapies sold by pharmaceutical giants in the crowded market.